Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer

[1] Camplejohn RS(1995)The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre Br J Cancer 71 140-145

[2] Ash CM(1995)Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869 Cytometry 22 297-306

[3] Gillett CE(1998)S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer Breast Cancer Res Treat 51 239-253

[4] Raikundalia B(1992)Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients J Clin Oncol 10 428-432

[5] Barnes DM(1997)Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer Br J Cancer 75 1525-1533

[6] Gregory WM(1990)Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry J Clin Oncol 8 2040-2046

[7] Richards MA(1997)Cell proliferation in 3,800 node-negative breast cancers: consistency over time of biological and clinical information provided by Int J Cancer 74 122-127

[8] Millis RR.(1999)H-thymidine labelling index J Natl Cancer Inst 91 271-278

[9] Kute TE(1997)Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer Clin Cancer Res 3 2471-2478

[10] Quadri Y(1992)Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy Cancer 69 470-475

[1] Camplejohn RS(1995)The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre Br J Cancer 71 140-145

[2] Ash CM(1995)Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869 Cytometry 22 297-306

[3] Gillett CE(1998)S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer Breast Cancer Res Treat 51 239-253

[4] Raikundalia B(1992)Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients J Clin Oncol 10 428-432

[5] Barnes DM(1997)Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer Br J Cancer 75 1525-1533

[6] Gregory WM(1990)Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry J Clin Oncol 8 2040-2046

[7] Richards MA(1997)Cell proliferation in 3,800 node-negative breast cancers: consistency over time of biological and clinical information provided by Int J Cancer 74 122-127

[8] Millis RR.(1999)H-thymidine labelling index J Natl Cancer Inst 91 271-278

[9] Kute TE(1997)Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer Clin Cancer Res 3 2471-2478

[10] Quadri Y(1992)Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy Cancer 69 470-475